Completed
PHASE1
INTERVENTIONAL
NCT06097390
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured. The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions. Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period). The treatment arm participants will be assigned to is decided by chance. The study will last for about 23 weeks for each participant. The study will enroll healthy male participants.
Interventions
Name:
Semaglutide
Type:
DRUG
Description:
Oral administration
Primary Outcomes
Measure:
Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve
TimeFrame:
From 0 to 24 hours after dosing on day 80 and 90
Description:
Measured in hour\*nanomoles per liter (h\*nmol/L).
Trial Information
NCT ID
NCT06097390
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025